| Literature DB >> 32496516 |
Nikolaus Jilg1, Pilar Garcia-Broncano2, Michael Peluso3, Florencia P Segal4, Ronald J Bosch5, Carla Roberts-Toler5, Samantha M Y Chen2, Cornelius N Van Dam6, Michael C Keefer7, Daniel R Kuritzkes4, Alan L Landay8, Steven Deeks3, Xu G Yu2, Paul E Sax4, Jonathan Z Li4.
Abstract
AIDS Clinical Trials Group study A5308 found reduced T-cell activation and exhaustion in human immunodeficiency virus (HIV) controllers start antiretroviral therapy (ART). We further assessed HIV-specific T-cell responses and post-ART viral loads. Before ART, the 31% of participants with persistently undetectable viremia had more robust HIV-specific T-cell responses. During ART, significant decreases were observed in a broad range of T-cell responses. Eight controllers in A5308 and the Study of the Consequences of the Protease Inhibitor Era (SCOPE) cohort showed no viremia above the level of quantification in the first 12 weeks after ART discontinuation. ART significantly reduced HIV-specific T-cell responses in HIV controllers but did not adversely affect controller status after ART discontinuation.Entities:
Keywords: HIV controllers; T-cell response; antiretroviral therapy; elite controllers; treatment interruption; viremic control
Mesh：
Substances：
Year: 2020 PMID： 32496516 PMCID： PMC7896274 DOI： 10.1093/infdis/jiaa294
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226